181 related articles for article (PubMed ID: 26508585)
1. Carbapenem use in French hospitals: A nationwide survey at the patient level.
Gauzit R; Pean Y; Alfandari S; Bru JP; Bedos JP; Rabaud C; Robert J; ; ;
Int J Antimicrob Agents; 2015 Dec; 46(6):707-12. PubMed ID: 26508585
[TBL] [Abstract][Full Text] [Related]
2. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
3. Higher third-generation cephalosporin prescription proportion is associated with lower probability of reducing carbapenem use: a nationwide retrospective study.
Muller A; Bertrand X; Rogues AM; Péfau M; Alfandari S; Gauzit R; Dumartin C; Gbaguidi-Haore H;
Antimicrob Resist Infect Control; 2018; 7():11. PubMed ID: 29387345
[TBL] [Abstract][Full Text] [Related]
4. Carbapenem-resistant enterobacteriaceae: an emerging problem in children.
Logan LK
Clin Infect Dis; 2012 Sep; 55(6):852-9. PubMed ID: 22700827
[TBL] [Abstract][Full Text] [Related]
5. Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae.
Prinapori R; Guinaud J; Khalil A; Lecuyer H; Gendrel D; Lortholary O; Nassif X; Viscoli C; Zahar JR
Am J Infect Control; 2013 Mar; 41(3):259-60. PubMed ID: 23062579
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic prescription in intensive care units in Latin America.
Curcio DJ;
Rev Argent Microbiol; 2011; 43(3):203-11. PubMed ID: 22430995
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system.
Ahmad F; Pogue JM; Marchaim D; Chopra T; Bheemreddy S; Lee J; Mudegowdra NS; Chaudhry A; Kaye KS
J Infect Public Health; 2014 Feb; 7(1):50-3. PubMed ID: 24210246
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of prior colonization and antibiotic use for third-generation cephalosporin-resistant enterobacteriaceae bacteremia in patients with sepsis.
Rottier WC; Bamberg YR; Dorigo-Zetsma JW; van der Linden PD; Ammerlaan HS; Bonten MJ
Clin Infect Dis; 2015 Jun; 60(11):1622-30. PubMed ID: 25694654
[TBL] [Abstract][Full Text] [Related]
10. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting.
Lew KY; Ng TM; Tan M; Tan SH; Lew EL; Ling LM; Ang B; Lye D; Teng CB
J Antimicrob Chemother; 2015 Apr; 70(4):1219-25. PubMed ID: 25473028
[TBL] [Abstract][Full Text] [Related]
11. Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol.
Garnier M; Gallah S; Vimont S; Benzerara Y; Labbe V; Constant AL; Siami S; Guerot E; Compain F; Mainardi JL; Montil M; Quesnel C;
BMJ Open; 2019 Feb; 9(2):e024561. PubMed ID: 30782909
[TBL] [Abstract][Full Text] [Related]
12. Faecal carriage of ESBL-producing Enterobacteriaceae and carbapenem-resistant Gram-negative bacilli in community settings.
Villar HE; Baserni MN; Jugo MB
J Infect Dev Ctries; 2013 Aug; 7(8):630-4. PubMed ID: 23949299
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals.
Papst L; Beović B; Pulcini C; Durante-Mangoni E; Rodríguez-Baño J; Kaye KS; Daikos GL; Raka L; Paul M;
Clin Microbiol Infect; 2018 Oct; 24(10):1070-1076. PubMed ID: 29410094
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
[TBL] [Abstract][Full Text] [Related]
15. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
Eser OK; Altun Uludağ H; Ergin A; Boral B; Sener B; Hasçelik G
Mikrobiyol Bul; 2014 Jan; 48(1):59-69. PubMed ID: 24506716
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Molecular and Phenotypic Methods for the Detection and Characterization of Carbapenem Resistant Enterobacteriaceae.
Somily AM; Garaween GA; Abukhalid N; Absar MM; Senok AC
Acta Microbiol Immunol Hung; 2016 Mar; 63(1):69-81. PubMed ID: 27020870
[TBL] [Abstract][Full Text] [Related]
17. Statewide surveillance of carbapenem-resistant enterobacteriaceae in Michigan.
Brennan BM; Coyle JR; Marchaim D; Pogue JM; Boehme M; Finks J; Malani AN; VerLee KE; Buckley BO; Mollon N; Sundin DR; Washer LL; Kaye KS
Infect Control Hosp Epidemiol; 2014 Apr; 35(4):342-9. PubMed ID: 24602937
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009.
Zilberberg MD; Shorr AF
J Hosp Med; 2013 Oct; 8(10):559-63. PubMed ID: 24022878
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.
Son SK; Lee NR; Ko JH; Choi JK; Moon SY; Joo EJ; Peck KR; Park DA
J Antimicrob Chemother; 2018 Oct; 73(10):2631-2642. PubMed ID: 29800480
[TBL] [Abstract][Full Text] [Related]
20. Clinical epidemiology of carbapenem-resistant enterobacteriaceae in community hospitals: a case-case-control study.
Lee GC; Lawson KA; Burgess DS
Ann Pharmacother; 2013 Sep; 47(9):1115-21. PubMed ID: 24259725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
